-
San Diego sheriff: Migrants did not try to forcefully stop school bus - August 31, 2024
-
One stabbed, another injured in altercation on L.A. Metro bus - August 31, 2024
-
Trump Judge Has ‘Two Options’ as Future of Case Unclear: Analyst - August 31, 2024
-
What to Know About Putin’s Planned Visit to Mongolia Amid ICC Arrest Warrant - August 31, 2024
-
Buying sex from a minor could be a felony under bill headed to Newsom - August 31, 2024
-
Democrat Lawmaker Switches Party to Become Republican - August 31, 2024
-
Misdated Mail-In Ballots Should Still Count, Pennsylvania Court Rules - August 31, 2024
-
Cause and manner of death determined for Lucy-Bleu Knight - August 31, 2024
-
NASCAR Craftsman Truck Series Announces Return To Iconic Circuit In 2025 - August 31, 2024
-
At Pennsylvania Rally, Trump Tries to Explain Arlington Cemetery Clash - August 31, 2024
Nobel Prize Awarded to Covid Vaccine Pioneers
The discovery “fundamentally changed our understanding of how mRNA interacts with our immune system,” the panel that awarded the prize said, adding that the work “contributed to the unprecedented rate of vaccine development during one of the greatest threats to human health in modern times.”
At first, other scientists were largely uninterested in taking up that new approach to vaccination. Their paper, published in 2005, was rejected by the journals Nature and Science, Dr. Weissman said. The study was eventually accepted by a niche publication called Immunity.
But two biotech companies soon took notice: Moderna, in the United States, and BioNTech, in Germany, where Dr. Karikó eventually became a senior vice president. The companies studied the use of mRNA vaccines for flu, cytomegalovirus and other illnesses. None moved out of clinical trials for years.
Then the coronavirus emerged.
Almost instantly, Drs. Karikó and Weissman’s work came together with several strands of disparate research to put vaccine makers ahead of the game in developing shots. That included research done in Canada that allowed fragile mRNA molecules to be safely delivered to human cells, and studies in the United States that pointed the way toward stabilizing the spike protein that coronaviruses used to invade cells.
By late 2020, less than a year into a pandemic that would eventually kill at least seven million people globally, regulators had authorized strikingly effective vaccines made by Moderna and by BioNTech, which partnered with Pfizer to produce its vaccine. Both used the modification Dr. Karikó and Dr. Weissman discovered.